Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s USV Joins Line-Up For Biosimilar Neulasta In Europe

Executive Summary

USV has joined the list of firms seeking clearance for biosimilar pegfilgrastim in Europe. Managing director Prashant Tewari says the company is “well geared” to address potential price competition and maintains that biosimilarity of USV’s pegfilgrastim with the innovator product has been established “satisfactorily”.

Advertisement

Related Content

USV Primes German Base With Juta Acquisition
USV Primes German Base With Juta Acquisition
First Biosimilar Neulasta In Final Stages Of EMA Review Process
First Biosimilar Neulasta In Final Stages Of EMA Review Process
Apotex's Neulasta, Neupogen Biosimilars Clear Legal Hurdles, But Approval Questions Remain
USV Seeks To Progress Oral Insulin In India

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel